Determining primary from secondary hyperparathyroidism: A review of current management

Corrigendum: Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review

[This corrects the article on p. 79 in vol. 8, PMID: 28473803.].

Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review

INTRODUCTION Primary hyperparathyroidism is increasingly an asymptomatic disease at diagnosis, but the recognized guidelines for management are based on evidence obtained from studies on patients with symptomatic disease, and surgery is not always indicated. Other patients are unable to undergo surgery, and thus a medical treatment is warranted. This systematic review provides an overview of th...

Current treatment options in secondary hyperparathyroidism.

Immunologic Differentiation of Primary Hyperparathyroidism from Hyperparathyroidism

A B S T R A C T Serum immunoreactive parathyroid hormone (IPTH) was measured by radioimmunoassay in 54 patients with primary hyperparathyroidism and in 18 consecutive patients with ectopic hyperparathyroidism due to nonparathyroid cancer without apparent skeletal metastasis. Although serum calcium concentration was higher in the group with ectopic hyperparathyroidism, serum IPTH was lower (rank...

Current status and treatment of primary hyperparathyroidism.

Primary hyperparathyroidism (HPT) is diagnosed in approximately 100,000 patients in the US each year, with a 2-3:1 female-to-male distribution. In most cases, occurrence is sporadic rather than familial, and 80% to 85% of cases of sporadic primary HPT are caused by a solitary parathyroid adenoma. The diagnosis is made by hypercalcemia with an inappropriately elevated parathyroid hormone (PTH) l...